ACADIA Pharmaceuticals Inc. research snapshot
ACAD AI stock analysis currently reads ACADIA Pharmaceuticals Inc. as a commercial-stage CNS biopharma with two approved products (NUPLAZID for Parkinson's disease psychosis and DAYBUE for Rett syndrome), about $851 million in cash and investments, and an AI score of 62 out of 100. The near-term catalyst calendar includes a Q2 2026 earnings release on August 4, 2026, an FDA Fast Track designation for pipeline candidate remlifanserin in Alzheimer's disease psychosis, and a pending European Commission decision on DAYBUE after a positive CHMP opinion. At the August 3, 2026 data cutoff, ACAD last closed near $25.87 with a market capitalization of about $4.43 billion and a neutral-to-bullish technical setup above its 50-day and 200-day moving averages. The trailing P/E of about 11.7x is misleading because TTM net income of $375.65 million includes a roughly $260 million one-time tax benefit, while the forward P/E near 64x to 79x better reflects low normalized earnings power. This page uses scenarios, technical levels, and source-backed facts. It is informational research, not investment advice.
Current price
$25.87
Market cap
$4.43 billion
AI score
62 / 100
Rating
Approved CNS franchise with strong cash, but low normalized earnings and an unproven DAYBUE EU launch limit conviction
Trend status
Consolidating in the upper half of its 52-week range after the late June CHMP rally, holding above the 50-day and 200-day moving averages near $23.70
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | ACADIA sells two approved CNS drugs: NUPLAZID for Parkinson's disease psychosis and DAYBUE for Rett syndrome. Revenue is growing but comes from a narrow two-product base. | Medium-high |
| Moat | Moderate, product-specific protection from FDA approval, orphan exclusivity (DAYBUE in the US through about 2030), specialist relationships, and manufacturing know-how. NUPLAZID faces rising competitive and patent timeline questions. | Medium |
| Management | New CEO Catherine Owen Adams (in place since late 2025) has a commercial operation and pipeline to manage. Insider ownership is very low at 0.56%, and shares outstanding rose about 2.7% year over year, so dilution is a monitoring item. | Medium |
| Financial trend | Revenue grew from about $484 million in FY2021 to $1.07 billion in FY2025 and roughly $1.10 billion TTM. GAAP profitability began in FY2024, but FY2025 and TTM net income were lifted by a large tax benefit, and Q1 FY2026 net income was only $3.64 million. | Medium-high |
| Valuation | Trailing P/E near 11.7x is optically low but distorted by the tax benefit. Forward P/E near 64x to 79x and P/S near 4.0x signal a growth-dependent valuation. EV/Revenue near 3.4x is reasonable for a biotech with two marketed products. | Medium |
| Technical trend | ACAD rallied from the $19.69 52-week low and jumped about 6.75% on June 26 when CHMP backed DAYBUE, then consolidated near $25 to $26.5. Price holds above the 50-day ($23.73) and 200-day ($23.66) moving averages with RSI near 56. | Medium-high |
| Risk level | Key risks are NUPLAZID competitive timing, DAYBUE EU commercial execution, low normalized earnings, an early-stage pipeline, dilution, short interest near 6.4% of shares outstanding, and the August 4, 2026 earnings event. | Medium-high |
| AI confidence | Medium-high confidence for the balance sheet, cash, revenue, market cap math, analyst consensus, and major risk categories. Lower confidence for normalized earnings power and forward P/E interpretation. | Medium-high data confidence |
| Investment certainty | Medium certainty. Products, cash, and catalysts support the thesis, but the stock already prices in DAYBUE EU success and pipeline progress, and the earnings base is uneven. | Medium |
ACAD AI stock forecast
The ACAD AI stock forecast uses scenario ranges around the $25.87 cutoff price. It does not claim that AI can predict a specific future price. The bullish case requires DAYBUE EU approval converting to real revenue, a strong Q2 2026 report, and remlifanserin Phase 2 progress. The base case assumes DAYBUE grows steadily while the market waits for clarity on normalized earnings and the EU decision. The bearish case assumes the Q2 2026 report disappoints, DAYBUE EU adoption stalls, or the tax benefit unwind forces lower earnings estimates.
$32 to $38
More likely if the August 4, 2026 Q2 report is strong, DAYBUE EU launch generates visible revenue by late 2027, NUPLAZID holds share, and remlifanserin or ACP-211 produces positive Phase 2 data, letting the market re-rate the stock toward the $36 to $37 analyst targets.
$26 to $31
More likely if DAYBUE grows at a moderate pace in the US and EU, NUPLAZID holds steady, the pipeline advances without binary events, and the stock trades near 3.7x to 4.4x price to sales on FY2026 revenue guidance of $1.22 to $1.28 billion.
$18 to $24
More likely if the Q2 report disappoints, DAYBUE EU adoption or reimbursement is slow, NUPLAZID faces accelerated competition, or the market re-rates the stock on low normalized earnings once the one-time tax benefit is removed.
ACAD AI technical analysis
ACAD AI technical analysis starts from the $25.87 close on July 31, 2026, used for this August 3, 2026 static page (the August 3 session traded near $25.6 to $25.7 at cutoff). The stock jumped about 6.75% on June 26, 2026 when CHMP backed DAYBUE, then consolidated between about $24.8 and $26.6. Price holds above the 50-day and 200-day moving averages. Because this page does not fetch request-time market data, traders should confirm levels on a live chart before acting.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $25.87 | Latest verified close (July 31, 2026) used for this page. The August 3, 2026 session traded near $25.6 to $25.7 at cutoff. |
| Near support | $24.80 to $25.10 | The late July consolidation lows. A daily close below this zone would put the moving-average cluster at risk. |
| Secondary support | $23.70 to $24.00 | The 50-day moving average area ($23.73) and the late June breakout shelf. This is the first trend-defining support zone. |
| Key support | $22.00 to $22.60 | The June base that preceded the CHMP catalyst. A sustained close below this zone would break the medium-term recovery structure. |
| Near resistance | $26.40 to $26.60 | The late July intraday highs. Breakout attempts need volume confirmation and ideally a positive Q2 2026 report or EU approval. |
| Major resistance | $28.00 to $28.35 | The 52-week high zone. Clearing it with above-average volume would open a test of analyst upside targets. |
| 50-day moving average | $23.73 | StockAnalysis statistics show ACAD above the 50-day moving average near $23.73 as of August 3, 2026, supporting the near-term trend. |
| 200-day moving average | $23.66 | ACAD also holds above the 200-day moving average near $23.66, confirming a medium-term positive trend from the 2026 lows. |
| Momentum | RSI near 56, price above both moving averages | RSI of 56.13 (StockAnalysis, August 3, 2026) is neutral to bullish and not yet overbought after the June rally. |
| Volume | About 1.53 million shares on July 31 | Volume was near the 1.35 million 20-day average. The June 26 CHMP day printed about 7.37 million shares, so a catalyst move should come with above-average participation. |
| Volatility | Beta 0.80; ATR 14 estimate near $1.10 to $1.40 | Daily ranges ran roughly $0.80 to $1.50 in July, so position sizing should allow for normal daily moves of 4% to 6% around the cutoff price. |
| Invalidation | Close below $23.66 to $23.73, then $22.00 | A close below the moving-average cluster weakens the near-term trend. A sustained close below $22.00 would challenge the medium-term recovery. |
ACAD AI trading strategy
The ACAD AI trading strategy is a rules-based framework, not personalized advice. It combines product and regulatory catalysts, technical confirmation, position sizing, and clear invalidation levels.
Look for ACAD to break above $26.60 and then $28.35 with above-average volume and positive Q2 2026 or EU approval news before treating the breakout as high conviction.
A failed breakout or a daily close below the 50-day area near $23.73 should reduce confidence in continuation.
If ACAD pulls back toward $24.80 to $25.10 without a negative product or regulatory change, compare price stabilization with the Q2 2026 report, EU decision timing, and quarterly revenue trajectory.
Do not average down solely because the balance sheet is strong. Define maximum loss, avoid sizing up ahead of the August 4 earnings print, and review pipeline timelines.
Track the August 4, 2026 Q2 earnings release, the European Commission decision on DAYBUE following the positive CHMP opinion, remlifanserin Phase 2 data and Fast Track progress, quarterly NUPLAZID and DAYBUE revenue, and dilution or insider patterns.
Reduce exposure if NUPLAZID revenue declines sequentially for two quarters, if DAYBUE EU launch faces pricing or reimbursement delays, or if the stock closes below the 200-day moving average.
Investment research summary
ACADIA discovers and commercializes CNS drugs for neurological and rare diseases, currently selling NUPLAZID for Parkinson's disease psychosis and DAYBUE for Rett syndrome, with an early pipeline led by remlifanserin.
The moat is moderate and product-specific: FDA approval and orphan exclusivity protect DAYBUE in Rett syndrome through about 2030 in the US, while NUPLAZID benefits from specialist relationships and being the only approved drug for Parkinson's disease psychosis. NUPLAZID patent and generic timelines need monitoring.
The thesis can fail if DAYBUE EU adoption is slow or poorly reimbursed, if NUPLAZID loses share or exclusivity sooner than expected, if the Q2 2026 report disappoints, or if the pipeline fails to deliver Phase 2 proof of concept. A specific trap is reading the 11.7x trailing P/E as cheap when TTM net income includes a roughly $260 million tax benefit and operating income is only about $81 million.
CEO Catherine Owen Adams, in place since late 2025, inherits a commercial operation with two approved products and a pipeline to advance. The team secured the positive CHMP opinion for DAYBUE, the Fast Track designation for remlifanserin, and the DAYBUE STIX reformulation. Insider ownership is very low at 0.56%, and equity dilution is an ongoing monitoring item.
CNS drug development remains a high-need area with aging populations and large unmet medical demand across Parkinson's disease psychosis, Alzheimer's disease psychosis, Rett syndrome, and depression. The trend is favorable for CNS-specialized biopharma, but clinical risk is high, regulatory hurdles are significant, and DAYBUE's Rett addressable market is small even at high per-patient value.
At the $25.87 cutoff price, ACAD trades near 11.7x trailing P/E (distorted by the tax benefit), about 64x to 79x forward P/E, and near 4.0x price to sales. The low trailing multiple is not a reliable value signal. The stock prices in DAYBUE EU growth and pipeline optionality while leaving limited room for a disappointing Q2 report or a slowdown in EU adoption.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| ACAD price | $25.87 close on July 31, 2026; August 3 intraday near $25.60 to $25.70 | Yahoo Finance and StockAnalysis | August 3, 2026 |
| Market capitalization | $4.43 billion, verified as $25.87 x 171.24 million shares (0.00% deviation) | financial_rigor.py market cap verification | August 3, 2026 |
| TTM revenue | $1.10 billion | Yahoo Finance and StockAnalysis | August 3, 2026 |
| TTM net income | $375.65 million (includes about $260 million one-time tax benefit) | Yahoo Finance and StockAnalysis | August 3, 2026 |
| Q1 FY2026 revenue | $268.06 million, below consensus of about $280 million | StockAnalysis and company release | August 3, 2026 |
| Q1 FY2026 net income | $3.64 million, EPS of $0.02 versus consensus of $0.08 | StockAnalysis and company release | August 3, 2026 |
| FY2025 revenue | $1.07 billion, up 11.9% from $957.80 million in FY2024 | StockAnalysis income statement | August 3, 2026 |
| Cash and investments | $851.46 million at Q1 FY2026, with net cash near $800 to $812 million | Yahoo Finance and StockAnalysis | August 3, 2026 |
| Total debt | About $39 million to $51 million, minimal; Debt/Equity near 4% to 6% | Yahoo Finance and StockAnalysis | August 3, 2026 |
| TTM free cash flow | $113.59 million (StockAnalysis); $154.14 million levered FCF (Yahoo Finance) | StockAnalysis and Yahoo Finance | August 3, 2026 |
| Valuation math | About 11.7x trailing P/E, 64x to 79x forward P/E, about 4.0x P/S, about 3.4x EV/Revenue, about 39x P/FCF from financial_rigor.py | financial_rigor.py valuation verification | August 3, 2026 |
| 52-week price range | $19.69 to $28.35 | Yahoo Finance and StockAnalysis | August 3, 2026 |
| Moving averages and momentum | 50-day MA $23.73, 200-day MA $23.66, RSI 56.13, beta 0.80 | StockAnalysis statistics | August 3, 2026 |
| Analyst consensus | Buy rating with $32.95 average price target from 21 analysts; range $17 to $45 | StockAnalysis analyst forecast | August 3, 2026 |
This ACAD AI stock analysis is an informational tool for research and education only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are scenarios based on available data as of August 3, 2026 and can be wrong. The gap between the trailing P/E and the forward P/E highlights the uncertainty in normalized earnings estimates, and the Q2 2026 earnings release on August 4, 2026 is a near-term risk event for all figures on this page.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
